TFS International is a leading, mid-size clinical Contract Research Organization providing global clinical development solutions.

TFS International is delighted to announce that Dr Andrew Copestake has accepted the position of Chief Commercial Officer and Executive Vice President, Global Business Development.

Dr Copestake is an entrepreneurial, commercially focused, senior executive with over 25 years’ experience in the pharmaceutical, biotechnology and CRO industry.

His most recent role was with Julius Clinical, a science-driven CRO based in the Netherlands, where he held the position of Chief Business Development Officer. 

Previous roles have included a number of senior leadership positions in business development and general management, including six years as CEO of a Swedish biotechnology company.

The majority of Andrew’s experience has been in international roles and he has lived and worked in the UK, US, Japan, Sweden and the Netherlands. He has managed diverse business development teams, and is proud of his record of achieving growth.

Andrew has proven leadership skills with an ability to manage businesses through significant change whilst achieving key operational and financial performance targets.

Andrew said of this new role, “I am very excited to be joining TFS.  As one of the leading mid-sized, global CROs, TFS is well placed to take advantage of the significant growth opportunity in this sector.  As we see many CROs increasing in scale, our customers are failing to experience increasing levels of service, whilst simultaneously facing rising costs, and reduced market choice.  By offering excellent customer experience combined with global capabilities and competitive pricing, TFS can present a truly differentiated service, which will result in significant benefits for clients, patients and employees. It will be my responsibility to help guide TFS through this exciting phase of development and I am grateful to János, the TFS board and the leadership team for offering me this wonderful opportunity.”